Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Albertsons Companies Inc (ACI) vs Cronos Group Inc (CRON) Price & Performance

Albertsons Companies Inc
Cronos Group Inc

Price performance

Price movement over the last 24 hours

Key statistics

Albertsons Companies Inc vs Cronos Group Inc — how do they compare? Albertsons Companies Inc trades at $14.26 (market cap $6.93B), while Cronos Group Inc trades at $2.74 (market cap $1.03B). The key difference: Albertsons Companies Inc is far larger — about 6.7× Cronos Group Inc's market cap, and Albertsons Companies Inc pays a 4.81% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.

ACICRON
Market Cap
$6.93B$1.03B
Sector
Consumer StaplesHealth
52-Week High
$22.33$3.27
52-Week Low
$13.45$1.95
Enterprise Value
$22.02B$205.93M
Dividend Yield
4.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Albertsons Companies Inc

Albertsons Companies (ACI) trades at $14.14, showing minimal daily movement with a 0.07% gain. The stock demonstrates strong earnings momentum with three consecutive quarterly beats, though profitability margins remain thin at 0.26% net income margin. Analyst consensus is bullish with a $18.75 price target representing 33% upside potential. Recent developments include AI-powered search enhancements and retail media partnerships driving innovation.

ACI presents a compelling value opportunity with attractive valuation metrics (P/S: 0.09, EV/EBITDA: 6.49) and consistent revenue growth, though investors face risks from declining profit margins, increasing debt levels, and competitive grocery market pressures. The technical picture remains bearish despite fundamental strengths.

Cronos Group Inc

Cronos Group (CRON) trades at $2.75, down 3.85% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 revenue growth of 40% year-over-year to $45.2 million, achieving record net revenue and gross profit. However, net income remains negative at -$9.45 million for 2025, though margins have improved significantly from prior years. Recent news highlights expansion in Canada and Israel, along with a share repurchase program extension.

Outlook is cautiously optimistic with strong revenue growth and market share gains, but profitability challenges and intense cannabis competition pose risks. Analyst sentiment is mixed with 60% hold ratings. Key catalysts include international expansion and execution on cost controls, while regulatory uncertainty and cash flow volatility remain headwinds for investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Albertsons Companies Inc

Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.

Read more on ACI

About Cronos Group Inc

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.

Read more on CRON